Mark McCamish, M.D., Ph.D.

President & Chief Executive Officer

Mark is President and Chief Executive Officer of Forty Seven, Inc. He is an international expert in biosimilars and biologics. Mark is passionate about mentoring and developing people while focusing on meeting patient needs through efficient, commercially viable efforts. He is a senior executive with extensive experience at multiple companies including Protein Design Labs, Abbott, Amgen, and Novartis-Sandoz. He led pioneering efforts in filing and launching biosimilars worldwide. He has demonstrated a commercial mindset in establishing research and development strategies leading to approvals and commercial success in multiple therapeutic areas and regulatory categories including biologics, biosimilars, drugs, devices, and medical foods. He held professorships at University of California, Davis and The Ohio State University.  After completing his Ph.D. in Human Nutrition from Penn State and MD from UCLA he completed Residency and Fellowship Training at the University of California, Davis. Mark received his bachelor’s and Master’s degrees from University of California, Santa Barbara.

Chris H. Takimoto, M.D., Ph.D, F.A.C.P.

Chief Medical Officer

Chris has over 25 years of experience in clinical oncology development and is the Chief Medical Officer of Forty Seven, Inc. Prior to Forty Seven, he held various positions at Johnson & Johnson ultimately becoming Vice President of Experimental Medicine Early Development for Oncology at Janssen R&D. In 2000, he became an Associate Professor at the University of Texas Health Science Center San Antonio (UTHSCSA), where he subsequently held the Zachry Chair for Translational Research at the Institute for Drug Development/Cancer Therapy & Research Center. He was also a Professor (Adjunct) of Pharmacology at UTHSCSA, and in 2007, he helped to found an independent Phase 1 oncology clinical research center called South Texas Accelerated Research Therapeutics (START). While in San Antonio, he was a principal or co-investigator on over 250 early phase oncology clinical trials. Prior to START, Chris served as a Senior Investigator in the National Cancer Institute’s (NCI) Medicine Branch, where he also completed fellowships in Medical Oncology at the NCI and Clinical Pharmacology at the Uniformed Services University. Chris received his M.D. and Ph.D. in Pharmacology from Yale University and did his undergraduate training in Chemistry at Stanford University. He has published over 160 research articles, reviews, editorials, and book chapters and he has served on the editorial board of numerous oncology publications.

Ann D. Rhoads

Chief Financial Officer

Ann has spent over 20 years in the life science industry and serves as the Chief Financial Officer of Forty Seven, Inc. Ms. Rhoads most recently served as Executive Vice President and Chief Financial Officer (CFO), Treasurer and Secretary of Zogenix, Inc. In this role, she oversaw all areas of financial management, raising approximately $400 million through Zogenix’s initial public offering and subsequent public equity and debt financings and facilitating the in-licensing of Zogenix’s lead product candidate, ZX008. Prior to joining Zogenix in 2010, Ms. Rhoads was Senior Vice President and CFO of Premier, Inc., where she executed a long-term strategic plan that resulted in 91% revenue growth from 2000 to 2009 and led the acquisition of two companies.  Earlier, she worked as a vice president at Sprout Group, the venture capital affiliate of Donaldson, Lufkin & Jenrette, as a consultant for Bain & Company, and as a member of the leveraged buyout and principal investment group at Merrill Lynch.  Ms. Rhoads holds an M.B.A. from the Harvard Graduate School of Business Administration and a B.S. with a concentration in Finance from the University of Arkansas.

Craig Gibbs, Ph.D., M.B.A.

Chief Business Officer

Craig has spent twenty-eight years in the biopharmaceutical industry including 24 years at Genentech and Gilead Sciences in a variety of research and business roles. He is passionate about translating scientific innovation into benefits for patients. Craig also serves on the Board of Directors of Aridis Pharmaceuticals and previously was on the Board of Directors and was Chairman of the Scientific Advisory Board of Tobira Therapeutics (acquired by Allergan). Prior to that, Craig spent 21 years at Gilead Sciences in leadership roles including Vice President of Commercial Strategy, Senior Director of Corporate Development and Senior Director and Head of Biology Research where he contributed to the development and launch of 12 FDA approved drugs. Prior to Gilead, Craig spent 3 years in the Protein Engineering Department at Genentech as a post-doctoral fellow. Craig has published over 50 scientific articles and is an inventor on 3 issued patents. He received his Ph.D. in Molecular Biology from the University of Glasgow, Scotland, a B.Sc. (Hons) in Biochemistry from Massey University, New Zealand and a M.B.A. from Golden Gate University, San Francisco, U.S.A.

Norman Kruse, Ph.D., J.D.

Chief Patent Counsel

Norm has more than 20 years of experience as a patent attorney in the biotechnology industry. Prior to joining Forty Seven, he was Vice President of Intellectual Property and Chief Patent Counsel at Verinata Health, and, after Verinata’s acquisition by Illumina, was a Senior Director of Intellectual Property at Illumina. Prior to that, Norm was Vice President of Intellectual Property and Chief Patent Counsel at Maxygen. During his 11 years at Maxygen, he developed, defended and enforced an industry-leading patent portfolio in directed molecular evolution (ranked #1 in the MIT Technology Review Patent Scorecard in 2003 for biotechnology patent estates). This patent portfolio also formed the basis for several successful companies spun out or sold by Maxygen including, Codexis (IPO in 2010), Verdia (acquired by DuPont) and Avidia (acquired by Amgen). Prior to Maxygen, Norm was a patent attorney at Chiron Corporation where he was responsible for Chiron’s gene therapy patent portfolio. He began his legal career as an attorney at Townsend and Townsend and Crew, working on biotechnology patent prosecution and strategy. He holds a Ph.D. in Biochemistry from the University of Washington, a J.D. from Golden Gate University School of Law in San Francisco, and received a B.S. in biochemistry from the University of California, Davis.

Kyle Elrod

VP Planning and Operations

Kyle has over twenty-eight years of experience in the pharmaceutical, diagnostic and life science industries. As the Vice President of Planning and Operations, Kyle manages company operations, project management, human resources and alliance management. Prior to joining Forty Seven, Kyle spent 8 years at Virobay where he was the Senior Vice President of Project Management and Operations. In that role, he was responsible for alliance management and company operations and successfully brought three protease inhibitors into clinical trials. Prior to Virobay, Kyle worked at Life Technologies as both an R&D Leader and a Program Director developing high throughput genetic sequencers. Prior to Life Technologies, Kyle served in positions of increasing responsibility at Celera Pharmaceuticals in South San Francisco culminating in a position as the Director of Research and Development Projects. During his twelve years at Celera, Kyle published over 22 scientific articles and was an inventor on 4 issued patents. He received a B.A. in Microbiology and Immunology from the University of California, Berkeley.

Jens-Peter Volkmer, M.D.

Founder and VP Research and Early Development

Jens is a founder of Forty Seven, Inc. and serves as the company’s VP of Research and Early Development. He oversees the company’s research to support the ongoing clinical trials and leads the development of new therapeutic programs. He is a physician-scientist with more than 10 years of experience conducting translational research in urology and immuno-oncology. Jens has played a leading role in developing the first-in-class anti-CD47 antibody through all stages of preclinical drug development to the first-in-human clinical trials. He conducted and directed proof-of-concept studies showing that anti-CD47 antibody therapy leads to a profound anti-tumor response by the innate and adaptive immune systems in various tumors. He has authored many publications and patents related to the CD47 program. Jens trained in Urology at the University of Duesseldorf and received his medical degree from the Heinrich-Heine University in Duesseldorf, Germany.

Mark Chao, M.D., Ph.D.

Founder and VP Clinical Development

Mark is a founder of Forty Seven Inc. and serves as the company’s Vice President of Clinical Development. He plays a leading role in the management of the company’s clinical trials and clinical development strategy. Mark is a physician-scientist who has spent over fifteen years conducting translational research in hematology/oncology and stem cell biology. Mark has played a key scientific and clinical role in the development of a first in class anti-CD47 antibody and subsequent first in human clinical trials. He conducted seminal research identifying the role of CD47 in cancer immune evasion and proof of concept studies demonstrating therapeutic efficacy of an anti-CD47 antibody in acute myeloid leukemia, non-Hodgkin’s lymphoma, and several solid tumors. He has authored numerous publications and patents in the CD47 field. Mark received his medical degree, Ph.D. in Cancer Biology and completed his hematology fellowship training at Stanford University. He received his B.A. in biology at Case Western Reserve University.

Qinghai Zhao, Ph.D.

VP Technical Development & Manufacturing

Qinghai has over 25 years of experience in biological CMC development and manufacturing and is the company’s Vice President of Technical Development and Manufacturing. Prior to Forty Seven, he was Vice President of CMC/Manufacturing at AnaptysBio.  Prior to that, he held various CMC leader positions including Head of CMC at NGM Biopharmaceuticals, Director of CMC Management at Teva Biologicals USA and Associate Director of Process Development at Cogenesys. Qinghai has extensive knowledge of all biological CMC functions with executive experience of developing CMC strategy from early stage to late stage for commercialization. Prior to Cogenesys, he was a Sr. Scientist of Lead Development at Human Genome Sciences and a Research Fellow at National Institute of Health and Georgetown University Lombardi Cancer Center. Qinghai received his Ph.D. for Biomedical Research at Uppsala University, Sweden.